Showing results (141-150 of 192) with videos related to

Sort By:
Pageof 20
Nature Medicine|May 27, 2025
Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trialEdmond M Kwan, Sarah W S Ng, Sofie H Tolmeijer, et al.
The Oncologist|April 24, 2025
Barriers to publishing early phase clinical trials: the oncologists' perspectiveMerel J J Lucassen, Pedro Bergmann, Olga Husson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2016
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in MelanomaAdil I Daud, Jedd D Wolchok, Caroline Robert, et al.
Clinical Genitourinary Cancer|May 7, 2019
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205Sebastien J Hotte, Kim N Chi, Anthony M Joshua, et al.
European Urology Oncology|February 22, 2026
WOMBAT (ANZUP 2201): A Phase 2, Single-arm Study of Bipolar Androgen Therapy in Patients with Nonmetastatic Castration-resistant Prostate Cancer with Prostate-specific Antigen Progression on DarolutamideBarak Talmor, Carole A Harris, Christopher Gianacas, et al.
The Lancet. Oncology|September 18, 2024
Sequential [<sup>177</sup>Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 studyArun A Azad, Mathias Bressel, Hsiang Tan, et al.
Translational Andrology and Urology|May 10, 2021
Whole blood <i>GRHL2</i> expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancerEdmond M Kwan, Heidi Fettke, Megan Crumbaker, et al.
Cancers|October 13, 2021
Relationship between Circulating Lipids and Cytokines in Metastatic Castration-Resistant Prostate CancerHui-Ming Lin, Nicole Yeung, Jordan F Hastings, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2020
Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanomaCaroline Robert, Wen-Jen Hwu, Omid Hamid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2018
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with PembrolizumabRichard W Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, et al.
Pageof 20